secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001651308-23-000141
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene receives EC approval for TEVIMBRA in ESCC; FDA accepts BLA for first-line ESCC
--------------------------------------------------------------------------------

- EC approved TEVIMBRA (tislelizumab) as monotherapy for adult patients with unresectable, locally advanced or metastatic ESCC after prior platinum-based chemotherapy.
- FDA accepted BLA for tislelizumab as first-line treatment for unresectable, recurrent, locally advanced, or metastatic ESCC; target action date H2 2024.
- Approval based on RATIONALE 302 trial: median OS 8.6 vs 6.3 months (HR 0.70; p=0.0001) for TEVIMBRA vs chemotherapy.
- FDA also granted Orphan Drug Designation for tislelizumab in previously untreated advanced or metastatic ESCC.
- BeiGene recently regained full global rights to TEVIMBRA; more than 750,000 patients prescribed to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000141/0001651308-23-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000141/bgne-20230919.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer